Research Centre Borstel news release
A new national cohort study from Latvia, conducted in collaboration with researchers from the clinical TB infrastructure (ClinTB) at the German Centre for Infection Research (DZIF) at the Research Centre Borstel, Leibniz Lung Centre (FZB), provides important insights into the treatment of multidrug-resistant TB. The study shows that long-term disease-free survival rates are significantly higher than previous standard indicators suggest. The results, published in The Lancet Regional Health Europe, are based on the analysis of data from 1,299 adult patients treated between 2005 and 2021.
Multidrug-resistant TB poses a significant challenge to healthcare systems worldwide. Whilst the effectiveness of treatment is traditionally assessed on the basis of treatment outcomes at the end of therapy, the new study shows that these criteria underestimate the actual long-term success of treatment. According to WHO standard definitions, only 4.8% of patients in Latvia were considered cured. However, during long-term follow-up, 76.9% of those affected remained permanently relapse-free.
Read the full news release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #13, 24 April 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Research Centre Borstel
Related HIV and Co-Infections News
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
Liverpool School of Tropical Medicine: New pooled testing toolkit to help expand TB diagnosis to ‘missed millions’
-
[Report] Physicians for Human Rights: Trump administration foreign policy approach to South Africa wastes billions of dollars, imperils global health
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.